Objectives: To evaluate clinical, radiological and immunohistochemichal profile of non small cell
lung carcinoma (NSCLC). Settings and study design: A cross sectional study conducted among
all diagnosed cases of primary lung malignancy in the Department of Respiratory
Medicine MES Medical College Perinthalmanna . Materials and methods: The 41 biopsy proven cases of NSCLC was
studied during a period of 1 ½ years, A detailed history, clinical evaluation
and the relevant investigation is done, small biopsy specimens are collected, a
histopathological evaluation was done and the markers Thyroid Transcription
Factor-1(TTF1), Epidermal Growth Factor
Receptor (EGFR) and p-63 status was determine by immunohistochemistry(IHC)
Results: Of the 41 cases, Squamous
cell carcinoma was the predominant histological type with a male predominance
and a peak incidence in 61-70 yrs of age. (58.53%) cases showed EGFR positivity.
TTF1 positivity was predominant with adenocarcinoma and p63 positivity with
squamous cell carcinoma. Smoking status and EGFR in adenocarcinoma shown that
there is a significant number of EGFR positivity associated with non-smokers
and all were females. The study could attain a 85.71% sensitivity and 92.59%
specificity for ttf1 in adenocarcinoma and 88% sensitivity and 100% specificity
for p63 in squamous cell carcinoma. Conclusion:
IHC can be used as a rapid and effective tool for diagnosing the histologic
type of NSCLC because of its high sensitivity and specificity. In
adenocarcinoma, there is a significant number of EGFR positivity associated
with non-smokers females.
Cancer Society. Cancer Facts and Figures 2011. Available at: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011
[2.] Antonio Marchetti, Carla Martella, Lara
Felicioni, Fabiobarassi, Simona Salvatore, Antonio Chella et al:EGFR Mutation
In Non – Small Cell Lung Cancer: Analysis of a Large Series of Cases And
Development of a Rapid and Sensitive Method for Diagnostic Screening With
Potential Implication on Pharmacologic Treatment. Journal of Clinical Oncology
Behera D, Epidemiology
of lung cancer – Global and Indian perspective Review article JIACM 2012; 13(2):
Binukumar Bhaskarapillai, Saina Sunil Kumar,
Satheesan Balasubramanian lung cancer in Malabar Cancer Centre in Kerala- A
Descriptive Analysis. Asian
Pacific Journal of Cancer Prevention, Vol 13, 2012 .
Choong NW, Salgia R, Vokes EE. Key signaling pathways and targets in lung cancer
therapy. Clin Lung Cancer 2007;
8 Suppl 2: S52-S60
Dhananjay Saranath and
Aparna Khanna, Current Status Of Cancer Burden: Global And Indian Scenario.
Biomedical Research Journal, 2014;1(1):1-5
D, Chin R Jr, McCain T, Case L, Harkness B, Oaks T, et al. Staging by positron
emission tomography predicts survival in patients with non-small cell lung
cancer. Chest 2001; 119(2): 333-339
SL, Roberts C, McKean ME, et al. Preoperative histological classification of
primary lung cancer: accuracy of diagnosis and use of the non-small cell
category. J Clin Pathol 2000;53:537–540.
facts and figures 2012
Haneda, Hidefumi Sasaki, Osamu Kawano, et al. A Correlation Between EGFR Gene
Mutation Status And Bronchoalveolar Carcinoma Features In Japanese Patients
With Adenocarcinoma; Jpn J Clin Oncol2006;36(2)69-75
Monographs on the Evaluation of Carcinogenic Risks to Humans VOLUME 83 Tobacco
Smoke and Involuntary Smoking. 2004.
M, Bubendorf L, Edelman M. J, Marchetti A, Mok5 T, Novello S, O’Byrne K,
Stahel, S. Peters R, Felip E & Panel Members. Second ESMO consensus
conference on lung cancer: pathology and molecular biomarkers for
non-small-cell lung cancer ;Annals of Oncology 25: 1681–1690, 2014.
and nadal’s trxt book of respiratory medicine. Fifth edition.
Guidelines for Patients. Lung Cancer Screening, Version 1.2014
NG: Value of thyroid transcription factor-1, E-c adherin, BG8, WT1, and CD44S
immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary
and nonpulmonary adenocarcinoma. Am J Surg Pathol 24:598-606, 2000
Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in
proportion among non-small cell lung cancer histologies. J Thorac Oncol
DK, Kris MG, Riely GJ. Use of cigarette-smoking history to estimate the
likelihood of mutations in epidermal growth factor receptor gene exons 19 and
21 in lung adenocarcinomas. J Clin Oncol 2006; 24: 1700–1704.
G, Pelosi G, Graziano P, Barbareschi M, Papotti M. A reevaluation of the
clinical significance of histological subtyping of non–small-cell lung
carcinoma: diagnostic algorithms in the era of personalized treatments. Int J
Surg Pathol 2009;17:206–218
LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA,
Kucherlapati R, Johnson BE, Lynch TJ: Response to treatment and survival of
patients with non-small cell lung cancer undergoing somatic EGFR mutation
testing. Oncologist 2007, 12:90–98
Vijayalakshmi Thanasekaran1, Dhanasekar1 T, Prathiba Duvooru, Clinicopathological and immunohistochemical
profile of non–small cell lung carcinoma in a tertiary care medical centre in
South India. Lung India • Vol 31 • Issue 1 • Jan - Mar 2014
HA, Fuhrer K, Cieply K, Yousem S. p63 expression in assessment of
bronchioloalveolar proliferations of the lung. Mod Pathol 2004;17:1134–40.
MN: Specific markers for pulmonary tumours. Histopathology 36:273-276, 2000
G, Fyfe N, King G, Chapman A, Kerr K M. Thyroid transcription factor 1 in
Pulmonary adenocarcinoma; J Clini Pathol 2004; 57:383-387.
AJ, Peto R, Doll R. Epidemiology of cancer. In: Oxford Textbook of Medicine.
Oxford, UK: Oxford University Press; 2010:299–332.
WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer
based on small biopsies and cytology: a paradigm shift. J Thorac Oncol
AS, Tang XM, Sabloff B. Clinicopathologic characteristics of the EGFR gene
mutation in non-small cell lung cancer. J Thorac Oncol 2006; 1: 231–239.
Valsamo K. Anagnostou, Konstantinos N. Syrigos,
Gerold Bepler, Robert J. Homer, and David L. Rimm. Thyroid Transcription Factor 1 Is an Independent
Prognostic Factor for Patients With Stage I Lung Adenocarcinoma; JOURNAL OF
CLINICAL ONCOLOGY:VOLUME 27:NUMBER 2:JANUARY 10 2009.
C, Wu YL, Chen G. Erlotinib versus chemotherapy as first-line treatment for
patients with advanced EGFR mutation-positive non small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label randomized phase 3 study.
Lancet Oncol 2011; 12: 735–7429